High hopes for PharmaEngine Inc’s (智擎生技) new drug for pancreatic cancer have sent the company’s shares rising 3.65 percent over the past week and 12.43 percent over the past month, with a Fubon analyst forecasting the Taipei-based company would see robust growth in earnings next year.
In her latest report, issued earlier last week, Fubon Securities Investment Services Co (富邦投顧) analyst Heather Chang (張雅雯) said PharmaEngine’s earnings per share (EPS) could surge to NT$21.47 next year, from this year’s forecast of NT$0.6, thanks to the anticipated sales contribution of new pancreatic cancer drug MM398.
The biopharmaceutical company is expected to receive US$75 million from the US-based Merrimack Pharmaceuticals Inc next year before MM398 can be sold on the market, and another US$130 million in milestone payments over the next three years if sales of the drug can reach certain targets, Chang said.
After that, PharmaEngine would likely receive royalty fees from the drug sales based on a licensing deal it signed with Merrimack two years ago for the development and commercialization of MM398 worldwide, with the exception of Taiwan.
“PharmaEngine is likely to gain royalty revenue of between NT$1.4 billion and NT$1.8 billion [US$47 million and US$60 million] if sales of MM398 hit US$1 billion, which is expected to contribute NT$14 to NT$18 to the company’s EPS,” Chang said on Monday last week.
Shares of PharmaEngine closed at NT$199 on the GRETAI Securities Market on Friday, up 6.42 percent from the previous session and the highest level in more than five months.
MM398 is presently undergoing phase-three clinical trials.
PharmaEngine said on Aug. 13 that the drug is likely to complete the third stage of clinical trials by the end of this year and hit the US, European and Taiwanese markets in September next year after obtaining drug permits.
PharmaEngine spokesman Peter Wu (吳兆升) said the company received US$15 million from Merrimack after they reached the licensing deal in May 2011 for US$220 million. The drug patent of MM398 will last until 2025, he said.
The market for pancreatic cancer drugs is about US$9 million a year in the US, according to an estimate by JPMorgan & Chase Bank.
Last week, Merrimack published its phase-two study results of the drug in the British Journal of Cancer, showing that 75 percent of patients surviving at least three months, with 25 percent reaching the one-year mark.
Pancreatic cancer is almost uniformly fatal, with a 73 percent death rate within one year of diagnosis, according to statistics compiled by the American Cancer Society. It has a five-year overall survival rate of about 6 percent in the US, based on the data from the National Cancer Institute.
Merrimack said in a press release on Thursday that its phase-two study showed median overall survival was 5.2 months, with 50 percent of patients presenting evidence of disease control. It expects the phase-three study to complete patient enrollment in the third quarter of this year.
“The speed of enrollment is faster than expected, suggesting promising results against pancreatic cancer,” Chang said in her report, adding that the US company is likely to release its phase-three study results by the end of the year.
Once the US Food and Drug Administration approves the sale of the drug in the US next year, it is expected to become an effective therapy option for patients with pancreatic cancer after gemcitabine has failed, significantly boosting PharmaEngine’s revenue and earnings, she said.
The company’s revenue is set to rise to NT$2.14 billion next year from this year’s estimated NT$187 million, while net profit would likely expand to NT$1.98 billion from NT$55 million over the same period, she added.
PharmaEngine is cautious about this year, but aims to swing to black next year due to contributions from MM398. The company posted losses of NT$10.62 million in the first quarter, with cumulative sales from January through last month totaling NT$20.32 million.
Additional reporting by Camaron Kao
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to